BPG is committed to discovery and dissemination of knowledge
Articles Published Processes Featured Articles Journals Submit a Manuscript
Cited by in CrossRef
For: Ridruejo E, Cacchione R, Villamil AG, Marciano S, Gadano AC, Mandó OG. Imatinib-induced fatal acute liver failure. World J Gastroenterol 2007; 13(48): 6608-6611 [PMID: 18161937 DOI: 10.3748/wjg.v13.i48.6608]
URL: https://www.wjgnet.com/1007-9327/full/v13/i48/6608.htm
(0) (0) (5590) (76)
Number Citing Articles
1
Nesrine S. El-Mezayen, Wessam F. El-Hadidy, Wessam M. El-Refaie, Th.I. Shalaby, Mahmoud M. Khattab, Aiman S. El-Khatib. Hepatic stellate cell-targeted imatinib nanomedicine versus conventional imatinib: A novel strategy with potent efficacy in experimental liver fibrosis. Journal of Controlled Release 2017; 266 doi: 10.1016/j.jconrel.2017.09.035
2
Michael J. Mauro, Michael W. Deininger. Management of Drug Toxicities in Chronic Myeloid Leukaemia. Best Practice & Research Clinical Haematology 2009; 22(3) doi: 10.1016/j.beha.2009.06.001
3
I. Diallo, S. B. Gning, F. Fall, B. Ndiaye, B. Fall, D. Irambona, M. Mbengue, P. S. Mbaye. Hépatotoxicité tardive à l’imatinib chez une patiente de 44 ans. Journal Africain d'Hépato-Gastroentérologie 2011; 5(3) doi: 10.1007/s12157-011-0273-3
4
Agnieszka Karbownik, Edyta Szałek, Katarzyna Sobańska, Tomasz Grabowski, Anna Wolc, Edmund Grześkowiak. Pharmacokinetic drug-drug interaction between erlotinib and paracetamol: A potential risk for clinical practice. European Journal of Pharmaceutical Sciences 2017; 102 doi: 10.1016/j.ejps.2017.02.028
5
Camille Houron, Marie Danielou, Olivier Mir, Bernard Fromenty, Gabriel Perlemuter, Cosmin Sebastian Voican. Multikinase inhibitor-induced liver injury in patients with cancer: A review for clinicians. Critical Reviews in Oncology/Hematology 2021; 157 doi: 10.1016/j.critrevonc.2020.103127
6
Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 2008; 17(7) doi: 10.1002/pds.1488
7
Simone Cunha Maradei, Angelo Maiolino, Alexandre Mello de Azevedo, Marta Colares, Luis Fernando Bouzas, Marcio Nucci. Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation. Blood 2009; 114(6) doi: 10.1182/blood-2009-03-212282
8
Mansour Tobaiqy, Nawal Helmi, Katie MacLure, Sylvia Saade. The prevalence of hepatic and thyroid toxicity associated with imatinib treatment of chronic myeloid leukaemia: a systematic review. International Journal of Clinical Pharmacy 2024; 46(2) doi: 10.1007/s11096-023-01671-0
9
Evelyn Li-Ching Chee, Adeline Yi Ling Lim, Pilar Modamio, Cecilia Fernandez-Lastra, Ignacio Segarra. Sunitinib tissue distribution changes after coadministration with ketoconazole in mice. European Journal of Drug Metabolism and Pharmacokinetics 2016; 41(3) doi: 10.1007/s13318-015-0264-7
10
O. Bouché, E. Scaglia, Z. Reguiai, V. Singha, H. Brixi-Benmansour, S. Lagarde. Biothérapies ciblées en cancérologie digestive : prise en charge de leurs effets secondaires. Gastroentérologie Clinique et Biologique 2009; 33(4) doi: 10.1016/j.gcb.2009.02.008
11
Víctor Blázquez-Ávila, Laura Rodríguez-Martín, María Concepción Álvarez-Cañas, Natalia De las Heras-Rodríguez. Hepatopatía crónica inmune-like por imatinib. Revista Española de Casos Clínicos en Medicina Interna 2024; 9(3) doi: 10.32818/reccmi.a9n3a4
12
Harshad Devarbhavi, Herbert L. Bonkovsky, Mark Russo, Naga Chalasani. Zakim and Boyer's Hepatology. 2018;  doi: 10.1016/B978-0-323-37591-7.00056-2
13
Gisele Pickering, Françoise Capriz. Médecine de la douleur. 2025;  doi: 10.3917/dunod.poisb.2025.01.2751
14
N.S. AL-Sowyan. Efficacy and Safety of Folic Acid During Toxic Hepatitis Induced by Acute Overdose of Paracetamol. International Journal of Pharmacology 2009; 5(3) doi: 10.3923/ijp.2009.208.214
15
J L Steegmann, M Baccarani, M Breccia, L F Casado, V García-Gutiérrez, A Hochhaus, D-W Kim, T D Kim, H J Khoury, P Le Coutre, J Mayer, D Milojkovic, K Porkka, D Rea, G Rosti, S Saussele, R Hehlmann, R E Clark. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 2016; 30(8) doi: 10.1038/leu.2016.104
16
Tao Shen, Yingxia Liu, Jia Shang, Qing Xie, Jun Li, Ming Yan, Jianming Xu, Junqi Niu, Jiajun Liu, Paul B. Watkins, Guruprasad P. Aithal, Raúl J. Andrade, Xiaoguang Dou, Lvfeng Yao, Fangfang Lv, Qi Wang, Yongguo Li, Xinmin Zhou, Yuexin Zhang, Peilan Zong, Bin Wan, Zhengsheng Zou, Dongliang Yang, Yuqiang Nie, Dongliang Li, Yuya Wang, Xi’an Han, Hui Zhuang, Yimin Mao, Chengwei Chen. Incidence and Etiology of Drug-Induced Liver Injury in Mainland China. Gastroenterology 2019; 156(8) doi: 10.1053/j.gastro.2019.02.002
17
Zhe Wang, Lili Jiang, Xiaoyu Wang, Hang Yin, Zhen Wang, Xin Lv, Yong Liu. Cabozantinib Carries the Risk of Drug-Drug Interactions via Inhibition of UDPglucuronosyltransferase (UGT) 1A9. Current Drug Metabolism 2022; 23(11) doi: 10.2174/1389200224666221028140652
18
Fang Cheng, Hongxiang Wang, Weiming Li, Yu Zhang. Clinical pharmacokinetics and drug–drug interactions of tyrosine-kinase inhibitors in chronic myeloid leukemia: A clinical perspective. Critical Reviews in Oncology/Hematology 2024; 195 doi: 10.1016/j.critrevonc.2024.104258
19
David D’Adamo. Advances in the treatment of gastrointestinal stromal tumor. Advances in Therapy 2009; 26(9) doi: 10.1007/s12325-009-0067-9
20
Asmaa Atteya, Aiman Ahmad, Dima Daghstani, Kamran Mushtaq, Mohamed A. Yassin. Evaluation of Hepatitis B Reactivation Among Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors. Cancer Control 2020; 27(1) doi: 10.1177/1073274820976594
21
Shan Babeendran, Ariel C. Soucie. Pain Management and Palliative Care. 2015;  doi: 10.1007/978-1-4939-2462-2_27
22
Qiang Shi, Xi Yang, Lijun Ren, William B. Mattes. Recent advances in understanding the hepatotoxicity associated with protein kinase inhibitors. Expert Opinion on Drug Metabolism & Toxicology 2020; 16(3) doi: 10.1080/17425255.2020.1727886
23
A. Frilling, M. Malago, G. Testa, E. Schleyer, F. Grabellus, R. Kronenberger, J. Li, C.E. Broelsch. Liver Transplantation for Metastasized Extragastrointestinal Stromal Tumor: A Case Report and an Overview of Literature. Transplantation Proceedings 2010; 42(9) doi: 10.1016/j.transproceed.2010.06.016
24
Gabriella Mezei, Árpád Illés, Péter Batár. A krónikus myeloid leukaemia tirozin-kináz-gátló kezelésének mellékhatásai és azok gyakorlati ellátása. Orvosi Hetilap 2021; 162(30) doi: 10.1556/650.2021.32177
25
Damian J. Harding, Gerry MacQuillan, Rebecca Howman, Bastian de Boer, Leon Adams, Andrew Mitchell, Gary Jeffrey. Successful Use of Dasatinib After Liver Transplantation for Imatinib-Induced Fulminant Liver Failure in Chronic Myeloid Leukemia. Journal of Clinical Oncology 2016; 34(11) doi: 10.1200/JCO.2013.50.1320
26
Adeline YL Lim, Ignacio Segarra, Srikumar Chakravarthi, Sufyan Akram, John P Judson. Histopathology and biochemistry analysis of the interaction between sunitinib and paracetamol in mice. BMC Pharmacology 2010; 10(1) doi: 10.1186/1471-2210-10-14
27
Cyrine Haidar, Sima Jeha. Drug interactions in childhood cancer. The Lancet Oncology 2011; 12(1) doi: 10.1016/S1470-2045(10)70105-4
28
Nelia Hernández, Fernando Bessone, Adriana Sánchez, María di Pace, Javier Brahm, Rodrigo Zapata, Ruby A. Chirino, Milagros Dávalos, Nahum Méndez-Sánchez, Marco Arrese, María Schinoni, M. Isabel Lucena, Raúl J. Andrade. Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. Annals of Hepatology 2014; 13(2) doi: 10.1016/S1665-2681(19)30886-5
29
Bruno Vincenzi, Grazia Armento, Mariella Spalato Ceruso, Giovanna Catania, Mark Leakos, Daniele Santini, Giorgio Minotti, Giuseppe Tonini. Drug-induced hepatotoxicity in cancer patients - implication for treatment. Expert Opinion on Drug Safety 2016; 15(9) doi: 10.1080/14740338.2016.1194824
30
Cristina Martínez Pascual, Mariano Valdés Mas, Jesús Miguel de la Peña Moral, Manuel Miras López. Hepatitis fulminante por imatinib en un paciente con leucemia mieloide crónica. Medicina Clínica 2011; 137(7) doi: 10.1016/j.medcli.2010.09.011
31
A. Bonvin, A. Mesnil, F. E. Nicolini, L. Cotte, M. Michallet, J. Descotes, T. Vial. Dasatinib-induced acute hepatitis. Leukemia & Lymphoma 2008; 49(8) doi: 10.1080/10428190802136384
32
Rashmi R. Shah, Joel Morganroth, Devron R. Shah. Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives. Drug Safety 2013; 36(7) doi: 10.1007/s40264-013-0048-4
33
Feng Jin, Dan Gao, Qin Wu, Feng Liu, Yuzong Chen, Chunyan Tan, Yuyang Jiang. Exploration of N-(2-aminoethyl)piperidine-4-carboxamide as a potential scaffold for development of VEGFR-2, ERK-2 and Abl-1 multikinase inhibitor. Bioorganic & Medicinal Chemistry 2013; 21(18) doi: 10.1016/j.bmc.2013.07.026
34
Amani Asnacios, Sylvie Naveau, Gabriel Perlemuter. Gastrointestinal toxicities of novel agents in cancer therapy. European Journal of Cancer 2009; 45 doi: 10.1016/S0959-8049(09)70047-4
35
Alaa E. El-Sisi, Samia S. Sokar, Hanaa A. Ibrahim, Sally E. Abu-Risha. Enhanced anticancer activity of combined treatment of imatinib and dipyridamole in solid Ehrlich carcinoma-bearing mice. Naunyn-Schmiedeberg's Archives of Pharmacology 2020; 393(6) doi: 10.1007/s00210-019-01803-2
36
Jian Ren Tan, Srikumar Chakravarthi, John Paul Judson, Nagaraja Haleagrahara, Ignacio Segarra. Potential protective effect of sunitinib after administration of diclofenac: biochemical and histopathological drug–drug interaction assessment in a mouse model. Naunyn-Schmiedeberg's Archives of Pharmacology 2013; 386(7) doi: 10.1007/s00210-013-0861-4
37
Ralph Yachoui. Early Onset Imatinib Mesylate–Induced Hepatotoxicity in a Patient With Gastrointestinal Stromal Tumors. American Journal of Therapeutics 2014; 21(5) doi: 10.1097/MJT.0b013e31826fc5d1
38
Shubhrat Purwar, Anam Fatima, Himashree Bhattacharyya, Lakshmi Venkata Simhachalam Kutikuppala, Matei-Alexandru Cozma, Bahadar Singh Srichawla, Leah Komer, Khulud Mahmood Nurani, Mihnea-Alexandru Găman. Toxicity of targeted anticancer treatments on the liver in myeloproliferative neoplasms. World Journal of Hepatology 2023; 15(9): 1021-1032 doi: 10.4254/wjh.v15.i9.1021
39
Ege Arzuk. Investigation of the role of NLRP3 inflammasome activation in new-generation BCR-ABL1 tyrosine kinase inhibitors-induced hepatotoxicity. Toxicology Letters 2024; 400 doi: 10.1016/j.toxlet.2024.08.007
40
Yi Rong, Nanxi Li, Xuan Qiao, Lei Yang, Peng Han, Zhiyun Meng, Hui Gan, Zhuona Wu, Xiaoxia Zhu, Yunbo Sun, Shuchen Liu, Guifang Dou, Ruolan Gu. Icaritin exhibits potential drug–drug interactions through the inhibition of human UDP‐glucuronosyltransferase in vitro. Biopharmaceutics & Drug Disposition 2024; 45(3) doi: 10.1002/bdd.2397
41
Yong Liu, Jacqueline Ramírez, Mark J. Ratain. Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors. British Journal of Clinical Pharmacology 2011; 71(6) doi: 10.1111/j.1365-2125.2011.03911.x
42
Cristina Martínez Pascual, Mariano Valdés Mas, Manuel Miras López. Respuesta. Medicina Clínica 2012; 138(14) doi: 10.1016/j.medcli.2011.10.005
43
Feng-Ru Huang, Wen-Tong Fang, Zi-Ping Cheng, Ye Shen, Dun-Jian Wang, Yong-Qing Wang, Lu-Ning Sun. Imatinib-induced hepatotoxicity via oxidative stress and activation of NLRP3 inflammasome: an in vitro and in vivo study. Archives of Toxicology 2022; 96(4) doi: 10.1007/s00204-022-03245-x
44
Haochen Jiang, Ying Jin, Hao Yan, Zhifei Xu, Bo Yang, Qiaojun He, Peihua Luo. Hepatotoxicity of FDA-approved small molecule kinase inhibitors. Expert Opinion on Drug Safety 2021; 20(3) doi: 10.1080/14740338.2021.1867104
45
Rebecca L Stone, Anil K Sood, Robert L Coleman. Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer. The Lancet Oncology 2010; 11(5) doi: 10.1016/S1470-2045(09)70362-6
46
Amina Haouala, Nicolas Widmer, Michel A. Duchosal, Michael Montemurro, Thierry Buclin, Laurent A. Decosterd. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood 2011; 117(8) doi: 10.1182/blood-2010-07-294330
47
Kirsty Wai-Chung Lee, Stephen Lam Chan. Hepatotoxicity of targeted therapy for cancer. Expert Opinion on Drug Metabolism & Toxicology 2016; 12(7) doi: 10.1080/17425255.2016.1190831
48
Susan A. Krikorian, Kanza Shamim. Adherence Issues for Oral Antineoplastics. American Journal of Lifestyle Medicine 2013; 7(3) doi: 10.1177/1559827612466996
49
Shivakumar Chitturi, Geoffrey C. Farrell. Schiff's Diseases of the Liver. 2011;  doi: 10.1002/9781119950509.ch27
50
Adrian Reuben, David G. Koch, William M. Lee. Drug-Induced Acute Liver Failure. Hepatology 2010; 52(6) doi: 10.1002/hep.23937
51
Tuncer Temel, Eren Gunduz, Esmira Sadigova, Hava Uskudar Teke, Safak Meric Ozgenel, Aysegul Harmanci Ozakyol. Hepatitis B Virus Reactivation under Treatment with Nilotinib. Euroasian Journal of Hepato-Gastroenterology 2015; 5(2) doi: 10.5005/jp-journals-10018-1147
52
Kathryn M Field, Chris Dow, Michael Michael. Part I: Liver function in oncology: biochemistry and beyond. The Lancet Oncology 2008; 9(11) doi: 10.1016/S1470-2045(08)70279-1
53
Paul M. Barr, Richard J. Creger, Nathan A. Berger. Adult Acute Lymphocytic Leukemia. 2011;  doi: 10.1007/978-1-60761-707-5_10
54
Austin C. Li, Erya Yu, Steven C. Ring, James P. Chovan. Structural identification of imatinib cyanide adducts by mass spectrometry and elucidation of bioactivation pathway. Rapid Communications in Mass Spectrometry 2014; 28(1) doi: 10.1002/rcm.6758
55
Esther Carcelero, Helena Anglada, Montse Tuset, Natalia Creus. Interactions between oral antineoplastic agents and concomitant medication: a systematic review. Expert Opinion on Drug Safety 2013; 12(3) doi: 10.1517/14740338.2013.784268
56
Mohammad Inamul Haq, Joanna Nixon, Adrian J Stanley. Imatinib and liver toxicity. BMJ Case Reports 2018; 11(1) doi: 10.1136/bcr-2018-226740
57
Isabelle Récoché, Vanessa Rousseau, Robert Bourrel, Maryse Lapeyre-Mestre, Leila Chebane, Fabien Despas, Jean-Louis Montastruc, Emmanuelle Bondon-Guitton. Drug–drug interactions with imatinib. Medicine 2016; 95(40) doi: 10.1097/MD.0000000000005076
58
Onder Tonyali, Ugur Coskun, Ramazan Yildiz, Tarkan Karakan, Umut Demirci, Nalan Akyurek, Mustafa Benekli, Suleyman Buyukberber. Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors. Medical Oncology 2010; 27(3) doi: 10.1007/s12032-009-9284-y
59
Morgane Clément, Jean-Paul Cervoni, Florian Renosi, Thierry Thévenot, Sophie Felix, Alexandre Doussot, Bruno Heyd, Éric Deconinck, Vincent Di Martino. Acute fulminant hepatitis related to the use of dasatinib: First case report. Clinics and Research in Hepatology and Gastroenterology 2022; 46(8) doi: 10.1016/j.clinre.2022.102004
60
Christoph Seidel, Martin Fenner, Florian Länger, Heike Bantel, Arnold Ganser, Viktor Grünwald. Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST). BMC Cancer 2012; 12(1) doi: 10.1186/1471-2407-12-186
61
Xin Lv, Zhe Wang, Zhen Wang, Hang Yin, Yangliu Xia, Lili Jiang, Yong Liu. Drug-drug interaction potentials of tucatinib inhibition of human UDP-glucuronosyltransferases. Chemico-Biological Interactions 2023; 381 doi: 10.1016/j.cbi.2023.110574
62
Gisèle Pickering, Aleksandra Kotlińska-Lemieszek, Nevenka Krcevski Skvarc, Denis O’Mahony, Fiammetta Monacelli, Roger Knaggs, Véronique Morel, Magdalena Kocot-Kępska. Pharmacological Pain Treatment in Older Persons. Drugs & Aging 2024; 41(12) doi: 10.1007/s40266-024-01151-8
63
Guilherme F. Perini, Fabio P.S. Santos, Vaneuza Funke, Jefferson Ruiz, Ben-Hur Ferraz Neto, Nelson Hamerschlak. Nilotinib post-liver transplantation for acute hepatic failure related to imatinib. Leukemia Research 2009; 33(12) doi: 10.1016/j.leukres.2009.06.012
64
Ji Min Han, Hye Sun Gwak. Reviews on the Hepatotoxicity of Tyrosine Kinase Inhibitors. Korean Journal of Clinical Pharmacy 2019; 29(4) doi: 10.24304/kjcp.2019.29.4.223
65
Judith A. Paice, Betty Ferrell. The management of cancer pain. CA: A Cancer Journal for Clinicians 2011; 61(3) doi: 10.3322/caac.20112
66
Douglas A. Keller, Richard J. Brennan, Karen L. Leach. Antitargets and Drug Safety. Methods and Principles in Medicinal Chemistry 2015;  doi: 10.1002/9783527673643.ch16
67
Ashraf Abugroun, Ahmed Chaudhary, Gabriel Rodriguez. Fatal Outcome of Imatinib in a Patient with Idiopathic Hypereosinophilic Syndrome. Case Reports in Oncological Medicine 2018; 2018 doi: 10.1155/2018/6291614
68
Mark Ayoub, Julton Tomanguillo, Carol Faris, Nadeem Anwar, Harleen Chela, Ebubekir Daglilar. SARS-CoV-2 Infection Is an Independent Risk Factor for Decompensation in Cirrhosis Patients. Diseases 2024; 12(3) doi: 10.3390/diseases12030046
69
Zhen Wang, Xin Lv, Hang Yin, Lili Jiang, Wenli Li, Yong Liu. High Risk of Drug–Drug Interactions Caused by Pexidartinib via UDP-Glucuronosyltransferases Inhibition. Chemical Research in Toxicology 2026; 39(2) doi: 10.1021/acs.chemrestox.5c00420
70
Emilia Neuwirt, Giovanni Magnani, Tamara Ćiković, Svenja Wöhrle, Larissa Fischer, Anna Kostina, Stephan Flemming, Nora J. Fischenich, Benedikt S. Saller, Oliver Gorka, Steffen Renner, Claudia Agarinis, Christian N. Parker, Andreas Boettcher, Christopher J. Farady, Rebecca Kesselring, Christopher Berlin, Rolf Backofen, Marta Rodriguez-Franco, Clemens Kreutz, Marco Prinz, Martina Tholen, Thomas Reinheckel, Thomas Ott, Christina J. Groß, Philipp J. Jost, Olaf Groß. Tyrosine kinase inhibitors can activate the NLRP3 inflammasome in myeloid cells through lysosomal damage and cell lysis. Science Signaling 2023; 16(768) doi: 10.1126/scisignal.abh1083
71
J. C. Kuo, S. Parakh, D. Yip. Regorafenib-induced hyperammonemic encephalopathy. Journal of Clinical Pharmacy and Therapeutics 2014; 39(4) doi: 10.1111/jcpt.12160
72
Lucas Souto Nacif, Daniel R. Waisberg, Rafael Soares Pinheiro, Fabiana Roberto Lima, Vinicius Rocha-Santos, Wellington Andraus, Luiz Carneiro D’Albuquerque. Imatinib-induced fulminant liver failure in chronic myeloid leukemia: role of liver transplant and second-generation tyrosine kinase inhibitors: a case report. Journal of Medical Case Reports 2018; 12(1) doi: 10.1186/s13256-018-1588-0
73
Franziska Paech, Jamal Bouitbir, Stephan Krähenbühl. Hepatocellular Toxicity Associated with Tyrosine Kinase Inhibitors: Mitochondrial Damage and Inhibition of Glycolysis. Frontiers in Pharmacology 2017; 8 doi: 10.3389/fphar.2017.00367
74
Analia Azaro, Mehmet Esat Demirhan, Joann Lim, Jordi Rodon. Phase I Oncology Drug Development. 2020;  doi: 10.1007/978-3-030-47682-3_18
75
E Jabbour, M Deininger, A Hochhaus. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 2011; 25(2) doi: 10.1038/leu.2010.215
76
Agnieszka Karbownik, Edyta Szałek, Katarzyna Sobańska, Tomasz Grabowski, Agnieszka Klupczynska, Szymon Plewa, Anna Wolc, Magdalena Magiera, Joanna Porażka, Zenon J. Kokot, Edmund Grześkowiak. The concomitant use of lapatinib and paracetamol - the risk of interaction. Investigational New Drugs 2018; 36(5) doi: 10.1007/s10637-018-0573-1
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.